| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
D-Fructose-6-phosphate is an endogenous metabolite that serves as a key intermediate in the Embden-Meyerhof glycolytic pathway. The interconversion of glucose-6-phosphate and fructose-6-phosphate, catalyzed by the enzyme phosphoglucose isomerase (PGI), is the second step of glycolysis. Fructose-6-phosphate is also the precursor for the synthesis of amino sugars such as galactosamine and glucosamine.
|
|---|---|
| ln Vitro |
In vitro, D-Fructose-6-phosphate serves as a substrate for several key metabolic enzymes including phosphofructokinase-1 (PFK-1), which converts it to fructose-1,6-bisphosphate, and glucosamine-6-phosphate synthase, which uses it for amino sugar biosynthesis. It also inhibits fructose-1,6-bisphosphatase (FBPase) in gluconeogenesis.
|
| ln Vivo |
In vivo, D-Fructose-6-phosphate is an endogenous metabolite in saliva that affects cell growth and autophagy. It is continuously produced and consumed in the glycolysis pathway and pentose phosphate pathway. Altered levels of fructose-6-phosphate have been implicated in metabolic disorders such as diabetes and cancer, where dysregulated glycolysis (Warburg effect) leads to abnormal accumulation of glycolytic intermediates.
|
| Enzyme Assay |
Enzymatic assays for phosphoglucose isomerase (PGI) are performed by incubating D-Fructose-6-phosphate with the enzyme and measuring the formation of glucose-6-phosphate. The reaction is conducted in Tris-HCl buffer at pH 7.4 and 30degC. Glucose-6-phosphate production is monitored spectrophotometrically at 340 nm using NADP+ and glucose-6-phosphate dehydrogenase as a coupling enzyme.
|
| Cell Assay |
Cell-based metabolic flux assays are performed using cancer cell lines (e.g., HeLa, A549) cultured in glucose-containing medium. Cells are treated with D-Fructose-6-phosphate or its disodium salt at concentrations of 1-20 mM. Metabolites are extracted with cold methanol, and glycolytic intermediates are analyzed by LC-MS/MS to assess flux through the glycolytic pathway and identify metabolic bottlenecks.
|
| Animal Protocol |
Animal studies examining fructose metabolism involve administering D-Fructose-6-phosphate disodium to rodents via intraperitoneal injection or tail vein injection. Liver and muscle tissues are harvested at various time points (0-60 minutes) and rapidly frozen. Glycolytic intermediates including fructose-6-phosphate, glucose-6-phosphate, and fructose-1,6-bisphosphate are measured in tissue extracts by enzymatic methods or LC-MS/MS.
|
| ADME/Pharmacokinetics |
As an endogenous glycolytic intermediate, D-Fructose-6-phosphate is rapidly metabolized in vivo. Under normal physiological conditions, its cellular concentration is tightly regulated and maintained at low micromolar levels. Exogenous administration leads to rapid conversion to downstream metabolites (fructose-1,6-bisphosphate, dihydroxyacetone phosphate, and glyceraldehyde-3-phosphate) via PFK-1 and aldolase.
|
| Toxicity/Toxicokinetics |
As an endogenous metabolite present in all living cells, D-Fructose-6-phosphate is generally non-toxic. The disodium salt form is safe for research use at typical concentrations. However, dysregulation of fructose-6-phosphate metabolism can contribute to pathological conditions such as insulin resistance, metabolic syndrome, and cancer progression when glycolytic flux is altered.
|
| References | |
| Additional Infomation |
D-fructose-6-phosphate disodium salt is a phosphate sugar.
D-Fructose-6-phosphate disodium salt is primarily used as a biochemical reagent for studying carbohydrate metabolism, glycolysis, gluconeogenesis, and the pentose phosphate pathway. It is also used to detect glucosamine-6-phosphate synthase and transaldolase (TAL) activities. The compound can be used in the study of Lewy body dementia and other metabolic disorders. Its molecular weight is 304.1, and it is soluble in water (up to 250 mg/mL). |
| Molecular Formula |
C6H11NA2O9P
|
|---|---|
| Molecular Weight |
304.10
|
| Exact Mass |
303.993
|
| CAS # |
26177-86-6
|
| PubChem CID |
22812950
|
| Appearance |
Solid powder
|
| Boiling Point |
692.5ºC at 760 mmHg
|
| Flash Point |
372.6ºC
|
| Vapour Pressure |
3.49E-22mmHg at 25°C
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
18
|
| Complexity |
262
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
P(=O)([O-])([O-])OC([H])([H])C([H])(C([H])(C([H])(C(C([H])([H])O[H])=O)O[H])O[H])O[H].[Na+].[Na+]
|
| InChi Key |
WJTRLMLMSLDAPQ-CCXTYWFUSA-L
|
| InChi Code |
InChI=1S/C6H13O9P.2Na/c7-1-3(8)5(10)6(11)4(9)2-15-16(12,13)14;;/h4-7,9-11H,1-2H2,(H2,12,13,14);;/q;2*+1/p-2/t4-,5-,6-;;/m1../s1
|
| Chemical Name |
disodium;[(2R,3R,4S)-2,3,4,6-tetrahydroxy-5-oxohexyl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 100 mg/mL (328.84 mM; with sonication)
DMSO : < 1 mg/mL (insoluble or slightly soluble) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (328.84 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonocation. (Please use freshly prepared in vivo formulations for optimal results.)
|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.2884 mL | 16.4420 mL | 32.8839 mL | |
| 5 mM | 0.6577 mL | 3.2884 mL | 6.5768 mL | |
| 10 mM | 0.3288 mL | 1.6442 mL | 3.2884 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
